RG6382
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 25, 2024
Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
(ACR Convergence 2024)
- P1 | "RO7507062 was designed as a next generation off-the-shelf B-cell depleter dedicated for patients with autoimmune diseases. A first-in-human study in patients with SLE is ongoing."
P1 data • B Cell Non-Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Lupus Erythematosus • CD20 • CD34
May 30, 2024
CHARACTERIZATION OF RO7507062, A CD19-TARGETING T-CELL BISPECIFIC ANTIBODY (CD19TCB), AND DESIGN OF A PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
(EULAR 2024)
- P1 | "RO7507062 was designed as a next generation off-the-shelf B-cell depleter dedicated for patients with autoimmune diseases. A first-in-human study in patients with SLE is ongoing."
P1 data • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Lupus Erythematosus • CD20 • CD34
November 03, 2023
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
April 28, 2023
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1 | N=70 | Not yet recruiting | Sponsor: Hoffmann-La Roche
New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 4
Of
4
Go to page
1